CONTACTS: Brianna Freeman, bfreeman@rinovum.com, 724-241-8936

The Stork® Home Conception Aid Lands In Australia.

Rinovum® Women’s Health launches the innovative home conception aid in new market.

PITTSBURGH, PA – Today, 1 in 6 Australian couples struggle with infertility. Limited options are available for those trying unsuccessfully to conceive. The pathway to parenthood can quickly become emotionally and financially exhausting. The Stork® helps bridge the gap between natural intercourse and in-clinic, assisted reproductive treatments such as intrauterine insemination (IUI) and in vitro fertilization (IVF).

The Stork offers a relaxed and private way of conceiving in the comfort of home using technology based on the well- established technique of cervical cap insemination. The device is included as a medical device on the Australian Register of Therapeutic Goods (ARTG) for home use without a prescription.

“Off the success of the US, Canada and UK launches, we were hopeful that Australians would respond positively to The Stork. Following the launch this week, we were absolutely thrilled to see its success continue across the pond. The response from Australia has been so positive and we are looking forward to seeing the journeys through to, hopefully, pregnancy.”

“The delivery of this innovative and potentially life changing product to Australia has been highly rewarding and we have been working collaboratively with Rinovum Women’s Health to fill the gap in conception options for Australians.”

Amanda Miller, Managing Director, Biccari Holdings P/L – the Australian distributor of The Stork at home conception aid.

The Stork uses a “condom-like” sheath for the collection of sperm and an easy-to-use “tampon-like” applicator, which delivers semen closer to the cervical opening. The technique of cervical cap insemination has a recorded success rate of around 20%, 1,2 which is comparable to IUI – with recorded success rates between 16-21%2,3. The Stork is designed to help couples with common fertility difficulties such as low sperm count, low sperm motility, unfavourable vaginal environment, ovulation timing and unexplained infertility.

The suggested retail price of The Stork, containing one single-use device is $129.95 and $349.95 for a Bundle Pack (three, single-use devices) and can be purchased online from http://storkconceptionaid.com.au/buy-now/. More information about The Stork can be found at www.storkconceptionaid.com.au. Here you can find how-to videos on the product and resources to help with trying to start a family.

“With so many people worldwide struggling to conceive, we are delighted to partner with Biccari Holdings Pty Ltd to make The Stork available in Australia, where 1 in 6 couples struggle with infertility. This product has helped many couples get closer to their goal of building a family, we are proud to now be able to support and help couples in Australia. What’s unique about this product is that it marries a well-established technique with new technology to allow couples to try to conceive naturally at home, without needing a prescription or a clinic visit.” said Stephen Bollinger, President and CEO of Rinovum Women’s Health and the creator of The Stork.

Australia marks the fourth market where The Stork products are available. The Stork home conception aid is available as The Stork in the United Kingdom and Canada. The Stork OTC® home conception aid is available in the US at pharmacies nationwide and online, as well as on the company website. Visit www.storkotc.com for more information on the US product, The Stork OTC.

About Biccari Holdings P/L
Biccari Holdings P/L is a private Australian owned company located in Queensland, with close to 30 years experience in supplying and marketing brands to Australian consumers through the pharmacy and grocery retail channels.
Together, Biccari Holdings P/L and Rinovum Women’s Health, LLC. have partnered to bring The Stork to Australia, giving the 1 in 6 couples struggling to start a family, a little extra nudge to becoming pregnant.

About Rinovum® Women’s Health, LLC
Rinovum Women’s Health is a privately held women’s health company dedicated to bringing products into the market that will enhance women’s lives and empower them to take charge of their health. The Stork Ib2C, Inc., A Rinovum Women’s Health Company, launches its flagship product, The Stork® OTC, which is a conception aid for reproductive health to assist in natural fertility and conception in the privacy of the patient’s home. Rinovum Women’s Health aims to support the development of products that are easy-to- use and safe, as well as a more economical way for a couple to address some of these issues. For more information about Rinovum Women’s Health, The Stork Ib2C, Inc., and The Stork products, visit www.rinovum.com and www.storkotc.com.

For further information, please contact:

Brianna Freeman
+1 724 241-8936
bfreeman@rinovum.com

1Corson SL, Batzar FR, Otis C, Fee D. The cervical cap for home artificial insemination. J Reprod. Med., 1986, May; 31 (5): 349-52.

2Subak et al. Therapeutic donor insemination: a prospective randomized trial of fresh versus frozen sperm. American Journal Obstetrics and Gynecology, 1992, June; 166 (6pt 1): 1597-604.

3American Society for Reproductive Medicine: http://www.reproductivefacts.org/FACTSHEET_Intrauterine_Insemination_IUI/

Click to Download